Startseite Kongressberichte 2021 2021 ASCO Annual Meeting Lung Cancer Lung Cancer—Non-Small Cell Metastatic

Lung Cancer—Non-Small Cell Metastatic

First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.

Martin Reck, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.

 CTI: NCT03215706

 

Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis.

Oladimeji Akinboro, Jonathon Joseph Vallejo, Pallavi Shruti Mishra-Kalyani, et al.

 

Pooled analyses of immune-related adverse events (irAEs) and efficacy from the phase 3 trials IMpower130, IMpower132, and IMpower150.
 
Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, et al.
 
 Clinical trial information: NCT02367781; NCT02657434; NCT02366143
 
Overall survival and exploratory subgroup analyses from the phase 2 CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS p.G12C mutated non-small cell lung cancer.
 
Ferdinandos Skoulidis, Bob T. Li, Ramaswamy Govindan, et al.
 
Clinical trial information: NCT03600883
 
SEE ALSO THE ARTICLE IN THE NEJM
 
Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practices.
 
Nicholas J. Robert, Esmond D. Nwokeji, Janet L. Espirito, et al. 
 
 
Racial disparities in biomarker testing and clinical trial enrollment in non-small cell lung cancer (NSCLC).
 
Debora S. Bruno, Lisa M. Hess, Xiaohong Li, et al. 
 
 
Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC), and potential biomarkers for response.
 
Joshua Bauml, Byoung Chul Cho, Keunchil Park, et al. 
 
Clinical trial information: NCT02609776
 
Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).
 
Pasi A. Janne, Christina S Baik, Wu-Chou Su, et al. 
 
 Clinical trial information: NCT03260491
 
Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations.
 
James Chih-Hsin Yang, Mengzhao Wang, Paul Mitchell, et al. 
 
 Clinical trial information: NCT03974022